查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1922902

丙型肝炎抗病毒藥物市場依產品類型、作用機制、治療類型、劑型、基因型、通路和最終用戶分類－2026-2032年全球預測

Antiviral Drugs for the Treatment of Hepatitis C Market by Product Type, Mechanism Of Action, Therapy Type, Formulation, Genotype, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，C型肝炎抗病毒藥物市場價值將達到 156.7 億美元，到 2026 年將成長至 168.7 億美元，到 2032 年將達到 278.9 億美元，複合年成長率為 8.57%。

關鍵市場統計數據
基準年 2025 156.7億美元
預計年份：2026年 168.7億美元
預測年份 2032 278.9億美元
複合年成長率 (%) 8.57%

針對不斷變化的丙型肝炎抗病毒治療格局，提供全面指導，並為決策者明確臨床、商業性和營運方面的優先事項。

丙型肝炎仍然是全球公共衛生領域的重點問題，其治療格局在過去十年中發生了快速變化。抗病毒科學的進步重新定義了臨床預期，使治療方案從副作用較多的長期療程轉變為針對特定病毒蛋白的短期高效抗病毒療法。這些治療進展從根本上改變了醫療服務提供者的行為、支付方的評估框架以及患者的期望，並持續影響著重點投資和創新領域。

快速的治療創新、價格壓力和不斷變化的經銷管道如何重塑臨床路徑、商業模式和生產選擇

治療創新徹底改變了丙型肝炎的整個治療流程，促進了新的商業模式和臨床路徑的出現。強效直接抗病毒藥物（DAA）的出現，使治療目標從病毒抑制轉變為持續病毒學反應（SVR），即接近治癒。這改變了轉診模式、檢測獎勵以及慢性病管理的經濟模式。因此，相關人員正在重新調整資源配置，致力於早期診斷、簡化治療流程以及採用泛基因型治療方法，從而減少對基因型特異性決策樹的需求。

評估關稅對2025年丙型肝炎藥物供應鏈韌性、採購行為、定價策略和病患獲取趨勢的影響

2025年關稅環境對C型肝炎抗病毒藥物領域的供應鏈、籌資策略和病患用藥途徑產生了多方面的影響。原料藥和製劑進口成本的上升迫使生產商和經銷商重新評估其全球籌資策略，加快對替代供應商的資格認證，並更多地依賴區域契約製造來降低成本波動。雖然這些措施在許多情況下維持了供應的連續性，但也前置作業時間，並增加了品質監管的複雜性。

以洞察為驅動的細分框架，將產品類型、作用機制、治療模式、通路、最終用戶、劑型和基因型與策略性商業性和臨床決策聯繫起來。

各細分市場的具體趨勢將決定丙型肝炎治療市場的臨床應用模式、商業性定位和營運重點。直接抗病毒藥物 (DAA)、干擾素和Ribavirin之間的差異持續影響處方行為和治療最佳化，其中 DAA 是現代治療方法的基礎，而干擾素和Ribavirin則在特定臨床環境中發揮重要作用。基於作用機制的細分有助於明確臨床價值提案：NS3/4A 蛋白酶抑制劑可快速抑制病毒，而 NS5A 抑制劑則能有效抑制複製複合物。此外，NS5B聚合酵素抑制劑分為核苷類和非核苷類，它們既具有增強的遺傳屏障特性，又能與其他藥物互補，從而有利於聯合治療的設計。

區域性指令和差異化准入策略旨在適應全球市場中不同的監管、採購和醫療服務提供。

區域趨勢將對丙型肝炎治療藥物的監管策略、取得途徑和商業性應用產生決定性影響。在美洲，支付方和公共衛生計畫優先考慮大規模篩檢工作和高效獲取泛基因型治療方案，鼓勵生產商將產品上市與國家消除目標相銜接，並在可能的情況下協商按療效付費協議。同時，私營和公共部門的定價談判要求企業證明其治癒導向型治療方案的實際價值和成本優勢。

藥物研發公司、非專利公司和生產合作夥伴之間的競爭動態和策略聯盟正在重新定義治療方法差異化和市場進入策略。

領先的製藥和生物技術公司的企業策略和競爭定位正在影響丙型肝炎治療的近期商業性成果和長期發展。現有創新藥物企業透過拓展適應症、覆蓋全基因型以及開展真實世界證據計畫來維持其高階市場地位，同時透過新製劑和簡化給藥方案來推進生命週期管理。同時，新參與企業和非專利生產商正在加劇價格敏感型細分市場的競爭，他們往往專注於批量競標和開拓新興市場。

為開發商和支付方提供可操作、高影響力的企業策略和臨床步驟，以確保永續取得、降低供應風險並加速以患者為中心的丙型肝炎治療。

產業領導者應優先採取一系列切實可行的措施，將洞察轉化為市場優勢。首先，投資泛基因型聯合治療以及能夠證明縮短療程可提高療效和安全性的證據至關重要。這些數據將減輕臨床醫生和支付方的負擔，並擴大其服務的患者群體。其次，建立靈活的生產網路和策略供應商關係將有助於降低關稅和前置作業時間風險。區域契約製造和關鍵中間體的雙重採購尤其有效。

採用穩健的混合調查方法，結合相關人員訪談、監管和臨床證據綜合以及情境分析，以檢驗策略洞見。

本執行摘要的研究採用了混合方法，兼顧與關鍵相關人員的直接對話和系統的二手證據綜合分析。主要研究包括對臨床醫生、支付方、採購專業人員以及製藥公司和契約製造組織的高階主管進行結構化訪談，從而獲得關於處方行為、競標趨勢和供應鏈限制的真實觀點。二手研究包括對同儕審查文獻、監管申報文件、臨床試驗註冊資訊和公共衛生計畫文件進行全面審查，以驗證臨床療效、安全性以及政策趨勢。

策略整合將治療方法進展、進入限制和業務永續營運連續性相結合，凸顯了推進治療方法和維持市場永續性的重要性。

總而言之，C型肝炎治療領域呈現出快速的科學進步、不斷變化的商業模式以及日益嚴峻的准入挑戰，這些因素共同為生產商、支付方和醫療保健系統帶來了緊迫性和機會。儘管治療方法的進步簡化了臨床決策並擴大了治癒的可能性，但價格壓力、關稅帶來的供應風險以及各地不同的需求都要求企業採取靈活的策略。那些能夠將臨床開發與可行的准入途徑相結合、實現生產和分銷管道多元化並投資於真實世界證據的機構，將更有利於實現商業性成功和公共衛生影響的雙重目標。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 丙型肝炎抗病毒藥物市場（依產品類型分類）

  • 直接作用抗病毒藥物
  • 干擾素
  • Ribavirin

9. 丙型肝炎抗病毒藥物市場依作用機轉分類

  • NS3/4A蛋白酶抑制劑
  • NS5A抑制劑
  • NS5B聚合酵素抑制劑
    • 非核苷類抑制劑
    • 核苷類抑制劑

10. 丙型肝炎抗病毒藥物市場（依治療方法）

  • 聯合治療
  • 單藥治療

第11章 丙型肝炎治療抗病毒藥物市場（依劑型分類）

  • 注射
  • 口服

第12章 丙型肝炎抗病毒藥物市場（依基因型分類）

  • 基因型 1
  • 基因型 2
  • 基因型 3
  • 基因型 4
  • 基因型 5
  • 基因型 6

第13章 丙型肝炎抗病毒藥物市場（依通路分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第14章 丙型肝炎抗病毒藥物市場（依最終用戶分類）

  • 診所
  • 居家醫療
  • 醫院

第15章 各地區C型肝炎抗病毒藥物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章 丙型肝炎抗病毒藥物市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 各國丙型肝炎抗病毒藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章：美國C型肝炎治療抗病毒藥物市場

第19章 中國C型肝炎治療抗病毒藥物市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hetero Drugs Limited
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Natco Pharma Limited
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Incorporated
  • Viatris Inc.
  • Zydus Cadila
Product Code: MRR-867BED9A9E44

The Antiviral Drugs for the Treatment of Hepatitis C Market was valued at USD 15.67 billion in 2025 and is projected to grow to USD 16.87 billion in 2026, with a CAGR of 8.57%, reaching USD 27.89 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 15.67 billion
Estimated Year [2026] USD 16.87 billion
Forecast Year [2032] USD 27.89 billion
CAGR (%) 8.57%

Comprehensive orientation to the evolving hepatitis C antiviral landscape that frames clinical, commercial, and operational priorities for decision-makers

Hepatitis C remains a global public health priority and the therapeutic landscape has undergone a rapid transformation over the past decade. Advances in antiviral science have redefined clinical expectations, shifting care from long, side-effect-heavy regimens to shorter, highly effective antiviral courses that target specific viral proteins. These therapeutic advances have fundamentally changed provider behavior, payer assessment frameworks, and patient expectations, and they continue to influence where investment and innovation are concentrated.

This executive summary synthesizes current clinical paradigms, reimbursement dynamics, and commercial strategies relevant to antiviral therapies for hepatitis C. It distills how drug classes and delivery formats intersect with genotype diversity and care settings, and it highlights the operational pressures reshaping R&D and manufacturing. The intent is to provide a strategic vantage point for executives, clinicians, and investors who must align program portfolios and market access plans to a rapidly evolving clinical and regulatory environment.

Throughout this overview, emphasis is placed on actionable interpretation rather than raw numbers, so readers can prioritize investments, anticipate access barriers, and adapt supply chains to maintain resilience and patient continuity of care.

How rapid therapeutic innovation, pricing pressure, and distribution channel evolution are reshaping clinical pathways, commercial models, and manufacturing choices

Therapeutic innovation has driven transformative shifts across the hepatitis C treatment continuum, catalyzing new commercial models and clinical pathways. The emergence of highly potent direct-acting antivirals has altered treatment objectives from viral suppression to sustained virologic response as a practical cure, which in turn has changed referral patterns, testing incentives, and the economics of chronic care management. As a result, stakeholders are refocusing resources on early diagnosis, simplified care algorithms, and pan-genotypic regimens that reduce the need for genotype-specific decision trees.

Simultaneously, scientific advances in mechanism-of-action targeting-spanning protease inhibitors, NS5A inhibitors and nucleoside and non-nucleoside polymerase inhibitors-have generated combination regimens that optimize efficacy while minimizing adverse events. These combination strategies, paired with oral formulations and shorter courses, are enabling expanded treatment in outpatient and homecare settings, prompting a redistribution of revenue and volume across distribution channels. At the same time, competitive pressure from generics and biosimilars has intensified pricing scrutiny, leading manufacturers to explore value-based contracting, bundled care models, and partnerships with payers and public health programs.

Operationally, manufacturers are rethinking manufacturing footprints and forging alliances with contract development and manufacturing organizations to increase flexibility and reduce time to market. Taken together, these shifts create both near-term disruption and long-term opportunities for differentiation through evidence generation, strategic channel engagement, and patient-centered access programs.

Assessment of how 2025 tariff measures are influencing supply chain resilience, procurement behavior, pricing strategies, and patient access dynamics for HCV antivirals

The tariff environment instituted in 2025 has introduced multifaceted implications for supply chains, procurement strategies, and patient access in the hepatitis C antiviral sector. Elevated import costs for active pharmaceutical ingredients and finished dosage forms have prompted manufacturers and distributors to re-evaluate global sourcing strategies, accelerate the qualification of alternate suppliers, and increase reliance on regional contract manufacturing to mitigate cost volatility. These responses have preserved supply continuity in many cases but have also introduced complexity into lead times and quality oversight.

Payer and procurement entities have responded by demanding greater transparency on landed cost and by seeking longer-term purchase agreements that can dampen short-term price shocks. In parallel, some manufacturers have absorbed tariff effects to protect market access for essential therapies, while others have adjusted pricing or delayed launches in specific markets to preserve margins. Clinicians and health systems face indirect consequences as formulary decisions and procurement cycles adapt, potentially affecting regimen availability and formulary positioning for certain formulations or branded products.

Looking ahead, industry players who proactively diversify manufacturing, optimize inventory policies, and engage with policymakers on tariff exemptions for essential medicines will be better positioned to preserve access and manage cost pressures. Coordination with distributors and health systems on demand forecasting and contingency planning remains critical to avoid therapy interruptions for patients living with hepatitis C.

Insight-driven segmentation framework that links product types, mechanisms, therapy models, channels, end users, formulations, and genotypes to strategic commercial and clinical decisions

Segment-specific dynamics determine clinical adoption patterns, commercial positioning, and operational priorities across the hepatitis C antiviral arena. Product type distinctions between direct-acting antivirals, interferons, and ribavirin continue to drive prescribing behavior and therapy optimization, with direct-acting antivirals serving as the backbone of modern regimens while interferons and ribavirin retain niche roles in select clinical circumstances. Mechanism-of-action segmentation delineates clinical value propositions: NS3/4A protease inhibitors deliver rapid viral suppression, NS5A inhibitors provide potent blockade of replication complexes, and NS5B polymerase inhibitors-subdivided into nucleoside and non-nucleoside inhibitors-contribute both high genetic barrier profiles and complementarity in combination therapy design.

Therapy-type considerations, namely combination therapy versus monotherapy, underlie efficacy and resistance management strategies, prompting manufacturers to focus development on synergistic combinations that can shorten treatment duration and enhance cure rates. Distribution channel dynamics across hospital pharmacies, online pharmacies and retail pharmacies affect patient access pathways, with ambulatory and homecare models expanding reach while hospital-centric channels remain critical for complex cases. End-user segmentation-spanning clinics, homecare and hospitals-shapes service delivery models, adherence support mechanisms and reimbursement codes that manufacturers must navigate. Formulation choices between injectable and oral options have profound implications for administration logistics, patient preference and adherence, while genotype diversity across genotypes 1 through 6 continues to influence trial design, labeling strategies and targeted launch sequencing. Together, these segmentation lenses inform portfolio prioritization, pricing strategies and clinical trial enrollment tactics.

Regional imperatives and differentiated access strategies that reconcile heterogeneous regulatory, procurement, and care-delivery landscapes across global markets

Regional dynamics exert a decisive influence over regulatory strategy, access pathways and commercial execution for hepatitis C antivirals. In the Americas, payers and public health programs prioritize large-scale screening initiatives and streamlined access to pan-genotypic regimens, which encourages manufacturers to align launches with national elimination goals and negotiate outcome-based contracts where feasible. Meanwhile, pricing negotiations within private and public sectors push companies to demonstrate real-world value and cost-offsets associated with cure-oriented therapy.

Across Europe, the Middle East & Africa, there is heterogeneity in regulatory timelines, reimbursement frameworks and health system capacity that necessitates tailored market access strategies. High-income European markets typically demand robust comparative-effectiveness evidence and post-launch pharmacovigilance, while many countries in the Middle East and Africa require capacity-building initiatives to support diagnosis and linkage to care. In turn, manufacturers must weigh localized clinical evidence generation and patient support programs against streamlined regulatory submissions when prioritizing resource allocation.

The Asia-Pacific region presents a complex mix of high-burden countries and mature markets, each with distinct procurement and manufacturing opportunities. Several countries in the region emphasize domestic production and tender-based procurement, influencing partnerships and licensing approaches. Collectively, these regional nuances require agile regulatory planning, differentiated pricing and distribution tactics, and investment in local stakeholder engagement to maximize therapeutic uptake and public health impact.

Competitive dynamics and strategic partnerships among innovators, generics, and manufacturing partners that are redefining therapeutic differentiation and market access approaches

Corporate strategies and competitive positioning among leading pharmaceutical and biotech companies are shaping both near-term commercial outcomes and the longer-term evolution of hepatitis C therapeutics. Established innovators continue to defend premium positioning through label expansions, pan-genotypic indications and real-world evidence programs, while simultaneously pursuing lifecycle management via new formulations and simplified dosing schedules. At the same time, entrants and generic manufacturers are intensifying competition in price-sensitive segments, often focusing on high-volume tenders and emerging market access.

Strategic alliances are increasingly common, with originators collaborating with regional partners to expand manufacturing capacity, secure distribution channels, and meet local market requirements. Research-focused organizations invest in next-generation polymerase and NS5A-targeted compounds to address resistance profiles and to create combination opportunities that can differentiate on safety and duration. Moreover, contract manufacturing organizations and specialty distributors are playing a larger role in enabling rapid scale-up and in supporting product launch logistics across diverse channels.

Investors and corporate leaders should monitor patent expiry timelines, litigation outcomes, and regulatory exclusivity windows closely, because these factors will dictate the timing of generic entry and influence pricing dynamics. Firms that combine robust clinical evidence with flexible manufacturing and pragmatic market access initiatives will be best positioned to sustain revenue streams while advancing public health objectives.

Actionable, high-impact corporate and clinical steps for developers and payers to secure sustainable access, mitigate supply risk, and accelerate patient-centered hepatitis C care

Industry leaders should prioritize a sequence of pragmatic actions to convert insight into market advantage. First, invest in pan-genotypic combination regimens and evidence that demonstrates short-course efficacy and improved safety, because such data reduce complexity for clinicians and payers and expand treatable populations. Next, establish flexible manufacturing networks and strategic supplier relationships to mitigate tariff exposure and reduce lead-time risk; regional contract manufacturing and dual-sourcing of key intermediates are particularly effective.

Simultaneously, develop integrated access strategies that align with payer expectations, including value-based contracting, outcome tracking and partnerships with public health programs to support screening and linkage to care. Expand channel strategies to include hospital pharmacies, retail and online pharmacies in coordinated ways that preserve adherence and data capture. Invest in digital adherence tools and patient support services that enable homecare delivery and remote monitoring, thereby reducing the burden on hospital systems and improving long-term outcomes. Finally, pursue targeted geographic launches that match genotype prevalence and health system readiness, and prioritize real-world evidence generation to support reimbursement discussions and to inform label expansions.

Robust mixed-methods research approach combining stakeholder interviews, regulatory and clinical evidence synthesis, and scenario analysis to validate strategic insights

The research underpinning this executive summary employed a mixed-methods approach that balanced primary stakeholder engagement with systematic secondary evidence synthesis. Primary research included structured interviews with clinicians, payers, procurement specialists, and senior executives across pharmaceutical and contract manufacturing organizations, which provided real-world perspectives on prescribing behavior, tender dynamics and supply-chain constraints. Secondary research involved a comprehensive review of peer-reviewed literature, regulatory filings, clinical trial registries, and public health program documentation to triangulate clinical efficacy, safety profiles and policy trends.

Analytical processes included cross-validation of qualitative insights against documented regulatory decisions and publicly available pharmacovigilance data. Scenario analysis was used to evaluate the operational implications of tariff changes and distribution shifts, while segmentation frameworks informed differential strategies across product classes, mechanisms of action, channels and genotypes. Limitations include variability in data transparency across regions and evolving tariff and policy environments; therefore, readers should interpret operational recommendations within the context of ongoing regulatory developments and local procurement practices.

Overall, the methodology emphasizes transparency, reproducibility and direct stakeholder validation to ensure that the recommendations reflect practical constraints and strategic opportunities encountered by market participants.

Strategic synthesis highlighting how clinical progress, access constraints, and operational resilience must be integrated to advance cures and sustain market viability

In summary, the hepatitis C antiviral landscape is characterized by rapid scientific progress, shifting commercial models, and evolving access challenges that together create both urgency and opportunity for manufacturers, payers and health systems. Therapeutic advances have simplified clinical decision-making and expanded the potential for cure, yet pricing pressure, tariff-driven supply risks and heterogeneous regional requirements necessitate agile strategies. Organizations that align clinical development with practical access pathways, diversify manufacturing and distribution arrangements, and invest in real-world evidence generation will achieve the dual objectives of commercial success and public health impact.

The strategic focus should remain on developing regimens that minimize complexity, expanding delivery models that reach underserved populations, and maintaining supply chain flexibility to withstand policy shocks. By integrating clinical differentiation with pragmatic market access planning and operational resilience, stakeholders can accelerate progress toward improved outcomes for people living with hepatitis C while navigating the commercial and regulatory headwinds present in today's global environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antiviral Drugs for the Treatment of Hepatitis C Market, by Product Type

  • 8.1. Direct-Acting Antivirals
  • 8.2. Interferons
  • 8.3. Ribavirin

9. Antiviral Drugs for the Treatment of Hepatitis C Market, by Mechanism Of Action

  • 9.1. NS3/4A Protease Inhibitors
  • 9.2. NS5A Inhibitors
  • 9.3. NS5B Polymerase Inhibitors
    • 9.3.1. Non-Nucleoside Inhibitors
    • 9.3.2. Nucleoside Inhibitors

10. Antiviral Drugs for the Treatment of Hepatitis C Market, by Therapy Type

  • 10.1. Combination Therapy
  • 10.2. Monotherapy

11. Antiviral Drugs for the Treatment of Hepatitis C Market, by Formulation

  • 11.1. Injectable
  • 11.2. Oral

12. Antiviral Drugs for the Treatment of Hepatitis C Market, by Genotype

  • 12.1. Genotype 1
  • 12.2. Genotype 2
  • 12.3. Genotype 3
  • 12.4. Genotype 4
  • 12.5. Genotype 5
  • 12.6. Genotype 6

13. Antiviral Drugs for the Treatment of Hepatitis C Market, by Distribution Channel

  • 13.1. Hospital Pharmacies
  • 13.2. Online Pharmacies
  • 13.3. Retail Pharmacies

14. Antiviral Drugs for the Treatment of Hepatitis C Market, by End User

  • 14.1. Clinics
  • 14.2. Homecare
  • 14.3. Hospitals

15. Antiviral Drugs for the Treatment of Hepatitis C Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Antiviral Drugs for the Treatment of Hepatitis C Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Antiviral Drugs for the Treatment of Hepatitis C Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Antiviral Drugs for the Treatment of Hepatitis C Market

19. China Antiviral Drugs for the Treatment of Hepatitis C Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. AbbVie Inc.
  • 20.6. AstraZeneca plc
  • 20.7. Aurobindo Pharma Limited
  • 20.8. Boehringer Ingelheim International GmbH
  • 20.9. Bristol-Myers Squibb Company
  • 20.10. Cipla Limited
  • 20.11. Dr. Reddy's Laboratories Ltd.
  • 20.12. F. Hoffmann-La Roche Ltd
  • 20.13. Gilead Sciences, Inc.
  • 20.14. GlaxoSmithKline plc
  • 20.15. Hetero Drugs Limited
  • 20.16. Johnson & Johnson
  • 20.17. Merck & Co., Inc.
  • 20.18. Natco Pharma Limited
  • 20.19. Novartis AG
  • 20.20. Pfizer Inc.
  • 20.21. Sun Pharmaceutical Industries Ltd.
  • 20.22. Teva Pharmaceutical Industries Ltd.
  • 20.23. Vertex Pharmaceuticals Incorporated
  • 20.24. Viatris Inc.
  • 20.25. Zydus Cadila

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DIRECT-ACTING ANTIVIRALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DIRECT-ACTING ANTIVIRALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DIRECT-ACTING ANTIVIRALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY INTERFERONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY INTERFERONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY RIBAVIRIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY RIBAVIRIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY RIBAVIRIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS3/4A PROTEASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5A INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5A INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5A INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NON-NUCLEOSIDE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NON-NUCLEOSIDE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NON-NUCLEOSIDE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NUCLEOSIDE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NUCLEOSIDE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NUCLEOSIDE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 1, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 1, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 1, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 2, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 2, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 2, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 3, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 3, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 3, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 4, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 4, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 4, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 5, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 5, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 5, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 6, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 6, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE 6, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. GCC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GCC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. GCC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 168. GCC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 169. GCC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. GCC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 171. GCC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 172. GCC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. GCC ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. G7 ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. G7 ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. G7 ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 195. G7 ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 196. G7 ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. G7 ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 198. G7 ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 199. G7 ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. G7 ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. NATO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. NATO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. NATO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 204. NATO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 205. NATO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. NATO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 207. NATO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 208. NATO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. NATO ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY GENOTYPE, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA ANTIVIRAL DRUGS FOR THE TREATMENT OF HEPATITIS C MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)